<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720850</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-LENAMA-022</org_study_id>
    <nct_id>NCT00720850</nct_id>
  </id_info>
  <brief_title>Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)</brief_title>
  <acronym>LENAMAINT</acronym>
  <official_title>Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that lenalidomide can be an effective drug in preventing&#xD;
      relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q&#xD;
      after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance a&#xD;
      T - or NK cell mediated graft versus leukemia (GVL) effects. Nevertheless, one has to keep in&#xD;
      mind a possible, yet unknown influence on modulation of clinical GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytogenetics are main predictors of outcome in patients with MDS and AML. In fact, a monosomy&#xD;
      5 (-5) or del5q (excluding typical 5q-syndrome) are mostly poor prognostic markers also&#xD;
      because being frequently part of a complex karyotype. Together, these patients often do not&#xD;
      respond to conventional chemotherapy and can only be cured by allogeneic HSCT. Nevertheless,&#xD;
      even after transplantation the relapse rate is considerably high and in the majority of&#xD;
      patient's relapses occur within the first year after HSCT.&#xD;
&#xD;
      Lenalidomide has been successfully used in MDS patients with del5q, irrespective of&#xD;
      additional cytogenetic abnormalities. Furthermore, in vitro studies have demonstrated also&#xD;
      impressive anti-proliferative effects of the compound in cell lines harbouring a monosomy 5.&#xD;
      Therefore, it seems to be a promising compound in preventing relapse of high-risk MDS or AML&#xD;
      patients with chromosomal abnormalities involving del5q or -5 after allogeneic HSCT. Due to&#xD;
      its immunomodulatory action it might also be able to enhance T - or NK cell mediated graft&#xD;
      versus leukemia effects. Nevertheless, it is unknown whether lenalidomide could modulate or&#xD;
      enhance clinical graft versus host disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment, scientific rationale not applicable anymore to all patients and possible&#xD;
    induction of GvHD by the study drug&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of relapse rate</measure>
    <time_frame>1 year post transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, Incidence and severity of acute and chronic GVHD, Safety</measure>
    <time_frame>1 year post transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT</description>
    <arm_group_label>lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Age &gt;=18 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  AML (&gt;/= 20% blasts) including secondary (s)AML (after radio-chemotherapy) with&#xD;
             karyotype abnormalities involving monosomy 5 or del5q or MDS and sMDS RAEB-1 and&#xD;
             RAEB-2 with karyotype abnormalities involving monosomy 5 or del5q or MDS and sMDS type&#xD;
             RA(+/-RS) or RCMD(+/-RS) only with complex karyotype abnormalities involving monosomy&#xD;
             5 or del5q&#xD;
&#xD;
          -  in complete hematological remission documented by bone marrow aspiration within 8-12&#xD;
             weeks after allogeneic HSCT&#xD;
&#xD;
          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must&#xD;
             have been discontinued at least 4 weeks prior to treatment in this study.&#xD;
&#xD;
          -  ECOG performance status of &lt;/= 2 at study entry.&#xD;
&#xD;
          -  Laboratory test results within these ranges:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1.0 x 10 9/L&#xD;
&#xD;
               -  Platelet count &gt;= 100 x 10 9/L&#xD;
&#xD;
               -  Serum creatinine &lt;= 2.0 mg/dL&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 mg/dL&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) &lt;= 5 x ULN&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)† must agree to use two reliable forms of&#xD;
             contraception simultaneously or to practice complete abstinence from heterosexual&#xD;
             intercourse during the following time periods related to this study: 1) for at least&#xD;
             28 days before starting study drug; 2) while participating in the study; and 3) for at&#xD;
             least 28 days after discontinuation from the study. The two methods of reliable&#xD;
             contraception must include one highly effective method (i.e. intrauterine device&#xD;
             (IUD), hormonal [birth control pills, injections, or implants], tubal ligation,&#xD;
             partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom,&#xD;
             diaphragm, cervical cap). FCBP must be referred to a qualified provider of&#xD;
             contraceptive methods if needed.&#xD;
&#xD;
          -  Disease free of prior malignancies for &gt;= 5 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast&#xD;
&#xD;
          -  Able to take aspirin (ASA) 100mg daily as prophylactic anticoagulation in case of&#xD;
             concomitant steroid treatment (patients intolerant to ASA may use low molecular weight&#xD;
             heparin).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  active uncontrolled acute GVHD overall grade 3-4&#xD;
&#xD;
          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking lenalidomide).&#xD;
&#xD;
          -  History of arterial or venous embolism or stroke&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          -  Use of any other experimental drug or therapy to treat MDS or AML within 28 days of&#xD;
             baseline (patients within a clinical trial evaluating new conditioning regimens are&#xD;
             allowed to participate in the LENAMAINT study)&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide or lenalidomide.&#xD;
&#xD;
          -  history of erythema nodosum if characterized by a desquamating rash while taking&#xD;
             thalidomide or similar drugs.&#xD;
&#xD;
          -  Known positive for HIV or infectious hepatitis, type A, B or C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, PD Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Dresden University of Technology, Medizinische Klinik und Poliklinik 1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dresden University of Technology, Medizinische Klinik und Poliklinik 1</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Medizinische Klinik und Poliklinik, Klinik für Hämatologie, Onkologie und klinische Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Knochenmarktransplantation</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hämatologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mk1dd.de</url>
    <description>Dresden University Hospital C. G. Carus, Medizinische Klinik und Poliklinik 1</description>
  </link>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>monosomy 5</keyword>
  <keyword>monosomy del5q</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

